At the recent American Urological Association annual meeting, researchers presented findings from a phase 3 trial showing that an experimental oral agent called enzalutamide (formerly MDV3100) prolonged survival by about five months among men with late-stage castrate-resistant prostate cancer (PCa) previously treated with docetaxel. If this drug is approved by the FDA, it would join a number of other agents already approved to treat late-stage PCa in the past few years, including sipuleucel-T, abiraterone, and cabazitaxel, all of which have different mechanisms of action.

With a growing number of options for men with late-stage PCa, Renal & Urology News would like to ask urologists the following question.

Do you think castrate-resistant prostate cancer can be considered a chronic illness in light of the new medications approved in recent years to treat it?
Leave a comment below to explain your choice.

Continue Reading